Systems biology and genomics of breast cancer.
暂无分享,去创建一个
[1] Annuska M Glas,et al. Gene expression profiles of primary breast tumors maintained in distant metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[3] A. Rosenberg,et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute SEER database , 2005 .
[4] M. Dunning,et al. PMC42, a breast progenitor cancer cell line, has normal-like mRNA and microRNA transcriptomes , 2008, Breast Cancer Research.
[5] Yi Zhang,et al. Genes associated with breast cancer metastatic to bone. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[7] Kenny Q. Ye,et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.
[8] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[9] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[10] Gavin D. Grant,et al. Common markers of proliferation , 2006, Nature Reviews Cancer.
[11] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[12] Nicholas J. Wang,et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.
[13] P. Pelicci,et al. Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content , 2010, Cell.
[14] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Ash A. Alizadeh,et al. Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.
[16] Charles M. Perou,et al. Triple-Negative Breast Cancer: Risk Factors to Potential Targets , 2008, Clinical Cancer Research.
[17] Zhiyuan Hu,et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] C. Perou,et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. , 2005, Cancer research.
[19] Jeffrey M. Rosen,et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.
[20] I. Ellis,et al. Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.
[21] C. Perou,et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. , 2007, Human pathology.
[22] S. Tavaré,et al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer , 2007, Genome Biology.
[23] A. Nobel,et al. The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.
[24] P. V. van Diest,et al. Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry , 2004, British Journal of Cancer.
[25] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[26] Puay Hoon Tan,et al. Conservation of Breast Cancer Molecular Subtypes and Transcriptional Patterns of Tumor Progression Across Distinct Ethnic Populations , 2004, Clinical Cancer Research.
[27] Jérôme Eeckhoute,et al. Positive Cross-Regulatory Loop Ties GATA-3 to Estrogen Receptor α Expression in Breast Cancer , 2007 .
[28] R. Beroukhim,et al. Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.
[29] A. Krasnitz,et al. Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients , 2010, Science Translational Medicine.
[30] J. Andersen,et al. Karyotypic evolution in breast carcinomas with i(1)(q10) and der(1;16)(q10;p10) as the primary chromosome abnormality. , 1999, Cancer genetics and cytogenetics.
[31] P. Johnston,et al. The role of BRCA1 in the cellular response to chemotherapy. , 2004, Journal of the National Cancer Institute.
[32] M. García-Closas,et al. Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study , 2007, Cancer Epidemiology Biomarkers & Prevention.
[33] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] John W M Martens,et al. Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.
[35] Zena Werb,et al. GATA-3 Maintains the Differentiation of the Luminal Cell Fate in the Mammary Gland , 2006, Cell.
[36] C. Perou,et al. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.
[37] W. Gerald,et al. Genes that mediate breast cancer metastasis to the brain , 2009, Nature.
[38] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[39] J. Pollard,et al. Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.
[40] Philippe Dessen,et al. Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array , 2009, Clinical Cancer Research.
[41] A. Rosenberg,et al. Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.
[42] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[43] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[44] Marco Marra,et al. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. , 2008, Cell stem cell.
[45] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[46] M. Teixeira,et al. Cytogenetic clues to breast carcinogenesis , 2002, Genes, chromosomes & cancer.
[47] Ajay N. Jain,et al. Breast tumor copy number aberration phenotypes and genomic instability , 2006, BMC Cancer.
[48] E. Dougherty,et al. Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.
[49] Daniel Birnbaum,et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.
[50] Charles M Perou,et al. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas , 2008, Breast Cancer Research.
[51] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[52] J Isola,et al. Molecular cytogenetics of primary breast cancer by CGH , 1998, Genes, chromosomes & cancer.
[53] G. Hortobagyi,et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] I. Fidler,et al. Metastasis results from preexisting variant cells within a malignant tumor. , 1977, Science.
[55] L. Bégin,et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.
[56] Hongjuan Zhao,et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.
[57] Zhiyuan Hu,et al. A compact VEGF signature associated with distant metastases and poor outcomes , 2009, BMC medicine.
[58] A. Regev,et al. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.
[59] Shridar Ganesan,et al. X chromosomal abnormalities in basal-like human breast cancer. , 2006, Cancer cell.
[60] C. Perou,et al. Molecular portraits and the family tree of cancer , 2002, Nature Genetics.
[61] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[62] C. Perou,et al. Mammary development meets cancer genomics , 2009, Nature Medicine.
[63] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[64] Jorma Isola,et al. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. , 2003, Cancer research.
[65] E. Lander,et al. A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.
[66] Ajay N. Jain,et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.
[67] R. Mass. The HER receptor family: a rich target for therapeutic development. , 2004, International journal of radiation oncology, biology, physics.
[68] Robert Tibshirani,et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.
[69] Jason I. Herschkowitz,et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.
[70] Jean-Marc Guinebretière,et al. A six-gene signature predicting breast cancer lung metastasis. , 2008, Cancer research.
[71] M. J. van de Vijver,et al. © 1997 Cancer Research Campaign , 2022 .
[72] Marie-Liesse Asselin-Labat,et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation , 2007, Nature Cell Biology.
[73] Charles M. Perou,et al. Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution , 2008, Clinical Cancer Research.
[74] C. Perou,et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] R. Strausberg,et al. Mutation of GATA3 in human breast tumors , 2004, Oncogene.
[76] Karla Kerlikowske,et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. , 2007, Cancer cell.
[77] William D. Foulkes,et al. Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .
[78] Therese Sørlie,et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer , 2007, Molecular oncology.
[79] M. Wicha. Cancer stem cell heterogeneity in hereditary breast cancer , 2008, Breast Cancer Research.
[80] L. Coussens,et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. , 2009, Cancer cell.
[81] Elmar Bucher,et al. Genome‐wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients , 2008, Genes, chromosomes & cancer.
[82] D. Patt,et al. Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC). , 2009 .
[83] Frank Pajonk,et al. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. , 2006, Journal of the National Cancer Institute.
[84] Andy J. Minn,et al. Genes that mediate breast cancer metastasis to lung , 2005, Nature.
[85] R. Spang,et al. Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[86] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[87] C. Cordon-Cardo,et al. A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.
[88] P. Nowell,et al. Chromosome studies on normal and leukemic human leukocytes. , 1960, Journal of the National Cancer Institute.
[89] J. Climent,et al. Characterization of breast cancer by array comparative genomic hybridization. , 2007, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[90] J. Eeckhoute,et al. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. , 2007, Cancer research.
[91] Susan G Hilsenbeck,et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.
[92] R. Cress,et al. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.
[93] M. Baudis. Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data , 2007, BMC Cancer.
[94] C. Perou,et al. In Vitro and In Vivo Analysis of B-Myb in Basal-Like Breast Cancer , 2008, Oncogene.
[95] Joel S. Parker,et al. Adjustment of systematic microarray data biases , 2004, Bioinform..
[96] W. Foulkes. BRCA1 functions as a breast stem cell regulator , 2004, Journal of Medical Genetics.
[97] Zhiyuan Hu,et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.
[98] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[99] Clifford A. Meyer,et al. Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.
[100] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[101] S. Fox,et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.
[102] R. Coates,et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA , 2008, Breast Cancer Research and Treatment.
[103] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[104] F. Pépin,et al. Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.